Evogene Ltd.

Foreign Filer Report • May 12, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2023

Commission File Number 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F.

品

Form 20-F 区 Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __________________________________________________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(0)(7): __________________________________________________

CONTENTS

Evogene Ltd. (the "Registran" or the "Company") her by and the Company approved all the proposals brought before the annual general meeting of shareholders held on May 11, 2023 (following a on-west also the "Meeting"), by the "Neeting"), by the respective requisite majority in acordance with the kneel Companis Law, 5739-199, and the Company's articles of assection, as decrear which was attached as Extibit 9.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission ("SEC"), on March 30, 2023, and sent in connection with the Meeting.

The contents of this Report of Form 6-K (this "Form 6-K") is incorporated by reference in the registration statements on Form F-3 (SECFile No. 33-25300), and Form S-6 (SEC File No. 33-1978, 33-2014), 33-20856 and 33-2.59215) of the Company, and will be a part there of rom the date on which this Form 6-K is submitted, to the extent superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Parsuant to the Securities Exclange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersiged, thereunto duly authorized.

EVOGENE LTD. (Registrant)

By: /s/ Yaron Eldad

Yaron Eldad Chief Financial Officer

3

Date: May 11, 2023